Integrated Medical, Pharmacy Claims Give Full View of AI Class
May 1
Some companies that analyze specialty drug spend do so with a focus solely on the pharmacy benefit. This approach, however, may fail to take into account a significant amount of medical benefit spending within certain conditions, including inflammatory diseases. A recent study by Prime Therapeutics LLC revealed trends across both benefits for the conditions, which account for almost 20% of all pharmacy and medical benefit drug expenditures among Prime’s commercially insured book of business. It also demonstrated that the class may benefit from indication-based pricing.
The study was presented at the Academy of Managed Care Pharmacy’s AMCP 2021 virtual conference in April.
Related Posts
May 11
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed Doses
READ MORE
May 11
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQvia
READ MORE
May 11
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’
READ MORE
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
